NOV 25, 2019 10:40 AM PST

eRapid: molecular diagnostic power in the palm of your hand

WRITTEN BY: Tara Fernandez

We’ve heard lofty biotech promises in the news of being able to diagnose diseases from a single drop of blood. Yet, diagnostic procedures for the majority of diseases still require lab-based techniques run by trained experts.

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University believe their new handheld electrochemical device, called “eRapid”, is capable of performing where other attempts at portable diagnostic devices have fallen short.

eRAPID: a Platform for Portable Diagnostics from Wyss Institute on Vimeo.

In the latest issue of Nature Nanotechnology, researchers Jonathan Sabaté del Río and colleagues describe a highly sensitive and inexpensive device that uses nanomaterial-coated sensors to pick up traces of disease biomarkers in biological samples.

The problem with existing technologies, such as glucometers used to quantify glucose levels in diabetics’ blood, is that over time, biological material from the sample can start to coat the sensors, rendering them inactive.

One way to impede this process, known as “biofouling”, is to coat sensors with various antifouling materials. However, this approach has proven to be an uphill battle for manufacturers of diagnostic devices, due to issues with consistency.

To tackle this challenge, the Wyss Institute engineers used a porous matrix of negatively-charged proteins as a coating, linked to the electrochemical sensors. This nanomaterial coating acted as a filter to keep positively-charged proteins in the blood from binding to the electrodes and blocking their action.

The difference this made to eRapid’s performance was impressive. Without the coating, sensors exposed to blood samples fizzled out in their ability to conduct signals within a day. On the other hand, coated sensors retained more than 90 percent of their sensitivity despite being immersed in a blood sample for a month.

Further testing revealed eRapid was capable of detecting diagnostic biomarkers with remarkable sensitivity: sensing up to a trillionth of a gram of these molecules within a single milliliter of blood.

What does the future hold for these next-generation diagnostic devices? By stacking multiple sensors in a single device, the inventors foresee eRapid becoming a widely-used portable, low-cost platform for clinical diagnostics and environmental testing alongside other applications. According to the authors, we can expect to see this potentially life-saving technology used everywhere from emergency situations to routine home care.

 

Sources: Harvard News, Nature Nanotechnology.

 

Photo credit: Wyss Institute at Harvard University

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
OCT 15, 2020
Cardiology
Measuring Pulse Transit Time as a Replacement for the Inflatable Cuff
OCT 15, 2020
Measuring Pulse Transit Time as a Replacement for the Inflatable Cuff
Many people deal with one disease or another every day of their life. Most require checking on things like blood sugar f ...
NOV 05, 2020
Clinical & Molecular DX
Painless Microneedle Patch Diagnoses Malaria in Minutes
NOV 05, 2020
Painless Microneedle Patch Diagnoses Malaria in Minutes
It looks like a Band-Aid — a small, adhesive patch that is applied directly to the skin. This simple, low-cost dia ...
JAN 18, 2021
Cancer
An "E-Nose" Could Help Doctors Diagnose Breast Cancer and Its Subtypes
JAN 18, 2021
An "E-Nose" Could Help Doctors Diagnose Breast Cancer and Its Subtypes
Breast cancer is one of the most well-studied cancers in modern medicine. Diagnostics can already differentiate between ...
JAN 26, 2021
Clinical & Molecular DX
Prostate Cancer Screening: No More False Positives
JAN 26, 2021
Prostate Cancer Screening: No More False Positives
A new diagnostic test powered by artificial intelligence has been found to detect prostate cancer markers in urine sampl ...
FEB 16, 2021
Genetics & Genomics
Genetic Tests That Look for Rare, Disease-Causing Variants are Usually Wrong
FEB 16, 2021
Genetic Tests That Look for Rare, Disease-Causing Variants are Usually Wrong
While people carry mostly the same genes, there are small differences in the sequences of those genes that can have prof ...
FEB 23, 2021
Clinical & Molecular DX
Dogs Versus AI-Powered Diagnostic Devices-Who Won?
FEB 23, 2021
Dogs Versus AI-Powered Diagnostic Devices-Who Won?
We’ve heard of dogs sniffing out cancer—an unsurprising skill given that they have over 200 million scent re ...
Loading Comments...